Patent Application
App. No. 14/070,256
COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY
Loading inventors, assignments & file history…
Abstract
New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
Claims (2)
1 . A method of extending median time to progression for responders by at least 13 months in patients with relapsed or refractory, low grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma, comprising administering four doses of 375 mg/m 2 of rituximab to the patients.
2 . A method according to claim 1 , wherein the patients exhibit an overall response rate to the administration of about 48%.
Assignments (3)
CHANGE OF NAME
Recorded Feb 25, 2016
From: IDEC PHARMACEUTICALS CORPORATION
To: BIOGEN IDEC INC.
Reel/Frame 037917/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 23, 2016
From: GRILLO-LOPEZ, ANTONIO J.
To: IDEC PHARMACEUTICALS CORPORATION
Reel/Frame 037800/0419 →